Fig. 3

PKC-δ silencing ameliorates FFA-induced L02 hepatocyte ERS. control siRNA group (NC), control siRNA + FFA group (NF), control siRNA + FFA + 10% high dose of HQT-medicated serum group (NH), PKC-δ siRNA group (SC), PKC-δ siRNA + FFA group (SF) and PKC-δ siRNA + FFA + 10% high dose of HQT-medicated serum group (SH). a and b Effects of HQT-medicated serum on the expression levels of total and phosphorylated PKC-δ protein and its mRNA in FFA-stimulated L02 cells. c and d Expression of total and phosphorylated PKC-δ protein and its mRNA after treatment with PKC-δ siRNA in different group of L02 cells. e, f and g Effects of HQT-medicated serum on the expression levels of p-PERK, p-IRE-1α, GRP78, ATF6, ATF4, CASPASE12, CHOP protein and the expression levels of GRP78, ATF6, XBP-1, CASPASE12, CHOP mRNA in FFA-stimulated L02 hepatocytes with or without transfection of PKC-δ siRNA. h Activity of Caspase-3 in FFA-stimulated L02 hepatocytes with or without transfection of PKC-δ siRNA. Results are expressed as mean ± S.D. ^*p < 0.05, ^**p < 0.01 vs CON group, ^#p < 0.05, ^##p < 0.01 vs FFA group. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001 vs NC group; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 vs NF group; ^&p < 0.05, ^&&p < 0.01, ^&&&p < 0.001, vs SC group; ^&* p < 0.05, ^&&* p < 0.01, ^&&* p < 0.01 vs SF group